title: Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.
authors.forename: Kevin M
authors.initials: KM
authors.lastname: Watt
authors.forename: Michael
authors.initials: M
authors.lastname: Cohen-Wolkowiez
authors.forename: Robert M
authors.initials: RM
authors.lastname: Ward
authors.forename: Daniel K
authors.initials: DK
authors.lastname: Benjamin
mesh_terms: D000935:Antifungal Agents / Q000493:pharmacokinetics*; D058387:Candidemia / Q000188:drug therapy*; D058365:Candidiasis, Invasive / Q000188:drug therapy*; D054714:Echinocandins / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D055666:Lipopeptides / Q000493:pharmacokinetics*; D008297:Male; D000077551:Micafungin
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077551:Micafungin